Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01732263 · ClinicalTrials.gov registry record · Phase 1

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

A Phase 1 study, sponsored by Shire.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target

NCT01732263 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01732263, a Phase 1 study, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.

Interventions

  • DRUG SSP-004184

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2012-11-09
Est. Completion 2013-04-01
Phase Phase 1

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT01732263

The ClinicalTrials.gov registry entry for NCT01732263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SSP-004184 is the first listed.

NCT01732263 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01732263 about?

NCT01732263 is a clinical study titled "Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function". The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal ...

What is the current status of trial NCT01732263?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-11-09. Estimated completion is 2013-04-01.

What interventions are being tested in trial NCT01732263?

The interventions under investigation include: SSP-004184 (DRUG).

Who is sponsoring clinical trial NCT01732263?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.